Hypoxia-inducible factors and neutrophil diversity in blood clotting in myeloproliferative neoplasms
Official title: Hypoxia-Inducible Factors and Neutrophil Heterogeneity in Myeloproliferative Neoplasm-Associated Venous Thrombosis
Funded at Univ of North Carolina Chapel Hill · NIH-11380793 · Data updated 2026-11-12
A physician-scientist is training over five years to uncover how low-oxygen signals and diverse neutrophils drive dangerous clots in people with myeloproliferative neoplasms, with the goal of finding new treatment targets.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $141,211 |
| NIH project number | 5K08HL163485-04 |
| Project ID | NIH-11380793 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with myeloproliferative neoplasms, particularly those with the JAK2V617F mutation, may benefit from future translational applications of this work.
✕Less likely to help
Patients without MPN or with non-thrombotic complications may not directly benefit from this specific research.
What this research studies
This grant supports a five-year career development path for a clinician-scientist focused on thrombotic mechanisms in myeloproliferative neoplasms (MPN). The work combines advanced laboratory models of thrombosis with translational training to build the foundations for an independent physician-scientist career. Mentored by experts in thrombosis and MPN, the recipient will gain skills through coursework, seminars, hands-on research, and advisory-committee mentoring. The scientific aim is to identify how thrombotic processes operate in JAK2V617F-positive MPN and how hypoxia-related factors and neutrophil diversity contribute to clot formation.
Why it matters
Potential benefit: If successful, the research could reveal new targets to prevent or treat blood clots in MPN patients and improve long-term outcomes.
How similar studies have gone: Previous work in related thrombosis models suggests targeted pathways can alter clotting; this project builds on foundational knowledge with a human-disease focus.
Where this research is happening
-
Univ of North Carolina Chapel Hill
Chapel Hill, United States Active
Researchers
- Principal investigator: Reeves, Brandi N — Univ of North Carolina Chapel Hill
- Study coordinator: Reeves, Brandi N
Related research
Other NIH-funded projects on the same topics.
-
Understanding blood clotting mechanisms in certain blood cancers
This study is looking into how blood clots form in people with myeloproliferative neoplasms (a type of blood cancer) to find new ways to help prevent serious complications, and it’s designed for patients who want to learn more about their condition and potential treatments.
-
Complement and clotting in JAK2V617F myeloproliferative neoplasms
A short, patient-friendly study will look at how a specific mutation in blood cells may trigger the body’s complement system to cause clots in people with myeloproliferative neoplasms.
-
Endothelial contribution to blood-clotting in myeloproliferative neoplasms
This project explores how the lining of blood vessels may drive dangerous clots in people with myeloproliferative neoplasms (MPNs).
-
Understanding how blood vessel cells contribute to blood clots in certain blood cancers
This study is looking at how certain cells in your blood vessels might contribute to blood clots in people with myeloproliferative neoplasms (MPNs), especially those with a specific mutation, and it aims to understand how current medications can help, with the possibility of you providing blood samples to assist in thi
-
Inherited genetic risks shaping myeloid cancer initiation
A research project at Boston Children’s Hospital is exploring how inherited genetic differences may push blood stem cells toward the start of myeloproliferative neoplasms, with potential implications for earlier detection and prevention.
-
Understanding why some myeloproliferative neoplasm patients resist interferon therapy
Researchers are studying why interferon-alpha works for some blood cancer patients but not others, by looking closely at stem cells from CALR-mutated myeloproliferative neoplasms.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.